Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters
- 1 November 2003
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (25) , 5512-5532
- https://doi.org/10.1021/jm0309349
Abstract
In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT(1A) and 5-HT(2A) receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT(1A) and 5-HT(2A) receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and alpha(2) receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K(i) < 25 nM and a NET/SERT ratio <10. Compound (-)-15j (coded as F-98214-TA for development studies) showed a dual binding profile with very high affinity values for SERT and NET (K(i) = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.Keywords
This publication has 24 references indexed in Scilit:
- The pharmacology of putative early-onset antidepressant strategiesEuropean Neuropsychopharmacology, 2002
- Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depressionBiological Psychiatry, 2002
- Past expectations, present disappointments, future hopes or psychopathology as the rate‐limiting step of progress in psychopharmacologyHuman Psychopharmacology: Clinical and Experimental, 2001
- Evidence of the Dual Mechanisms of Action of VenlafaxineArchives of General Psychiatry, 2000
- Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic AgentsJournal of Medicinal Chemistry, 2000
- Neurokinin receptor antagonistsExpert Opinion on Investigational Drugs, 2000
- Sharing the responsibilities: the roles of the governmentInternational Clinical Psychopharmacology, 1999
- Antidepressants and the brainInternational Clinical Psychopharmacology, 1999
- The human pharmacology of reboxetineHuman Psychopharmacology: Clinical and Experimental, 1998
- The effects of mirtazapine on central noradrenergic and serotonergic neurotransmissionInternational Clinical Psychopharmacology, 1995